br Liu C Wu J Paudyal SC You Z and
 Liu C, Wu J, Paudyal SC, You Z, and Yu X (2013). CHFR is important for the first wave of ubiquitination at DNA damage sites. Nucleic Acids Res 41, 1698–1710.  Kawasaki T, Ohnishi M, Suemoto Y, Kirkner GJ, Liu Z, Yamamoto H, Loda M, Fuchs CS, and Ogino S (2007). WRN promoter methylation possibly connects mucinous differentiation, microsatellite instability and CpG island methylator Amiloride in colorectal cancer. Mod Pathol 21, 150.
 Masuda K, Banno K, Yanokura M, Tsuji K, Kobayashi Y, Kisu I, Ueki A, Yamagami W, Nomura H, and Tominaga E, et al (2012). Association of epigenetic inactivation of the WRN gene with anticancer drug sensitivity in cervical cancer cells. Oncol Rep 28, 1146–1152.
 Wang L, Xie L, Wang J, Shen J, and Liu B (2013). Correlation between the methylation of SULF2 and WRN promoter and the irinotecan chemosensitivity in gastric cancer. BMC Gastroenterol 13, 173.
 Tessema M, Yingling CM, Thomas CL, Klinge DM, Bernauer AM, Liu Y, Dacic S, Siegfried JM, Dahlberg SE, and Schiller JH, et al (2012). SULF2 methylation is prognostic for lung cancer survival and increases sensitivity to topoisomerase-I inhibitors via induction of ISG15. Oncogene 31, 4107–4116.
 Brandes JC, van Engeland M, Wouters KA, Weijenberg MP, and Herman JG (2005). CHFR promoter hypermethylation in colon cancer correlates with the microsatellite instability phenotype. Carcinogenesis 26, 1152–1156.  Overman M, Adam L, Raghav K, Wang J, Kee B, Fogelman D, Eng C, Vilar E, Shroff R, and Dasari A, et al (2018). Phase II study of nab-paclitaxel in refractory small bowel adenocarcinoma and CpG island methylator phenotype (CIMP)-high colorectal cancer. Ann Oncol 29, 139–144.  Scolnick DM and Halazonetis TD (2000). Chfr defines a mitotic stress checkpoint that delays entry into metaphase. Nature 406, 430–435.
 Ogi K, Toyota M, Mita H, Satoh A, Kashima L, Sasaki Y, Suzuki H, Akino K, Nishikawa N, and Noguchi M, et al (2005). Small interfering RNA-induced CHFR silencing sensitizes oral squamous cell cancer cells to microtubule inhibitors. Cancer Biol Ther 4, 773–780.
 Derks S, Cleven AH, Melotte V, Smits KM, Brandes JC, Azad N, van Criekinge W, de Bruine AP, Herman JG, and van Engeland M (2014). Emerging evidence for CHFR as a cancer biomarker: from tumor biology to precision medicine. Cancer Metastasis Rev 33, 161–171.
 Ford EE, Grimmer MR, Stolzenburg S, Bogdanovic O, de Mendoza A, Farnham PJ, Blancafort P, and Lister R (2017). Frequent lack of repressive capacity of promoter DNA methylation identified through genome-wide epigenomic manipulation. bioRxiv . http://dx.doi.org/10.1101/170506.
Available online at www.sciencedirect.com
Association of clinical outcomes in metastatic breast cancer patients with circulating tumour cell and circulating cell-free DNA
Zhong Ye a,1, Chun Wang a,1, Shaogui Wan b,1, Zhaomei Mu c, Zhenchao Zhang a, Maysa M. Abu-Khalaf a, Frederick M. Fellin a, Daniel P. Silver a, Manish Neupane a, Rebecca J. Jaslow a,
Saveri Bhattacharya a, Theodore N. Tsangaris a, Inna Chervoneva d, Adam Berger e, Laura Austin a, Juan P. Palazzo f, Ronald E. Myers a, Neha Pancholy a, Darayus Toorkey a, Kaelan Yao a, Max Krall a, Xiuling Li g, Xiaobing Chen h, Xiuhong Fu i, Jinliang Xing j, Lifang Hou k, Qiang Wei l, Bingshan Li l, Massimo Cristofanilli c,**, Hushan Yang a,*
a Department of Medical Oncology, Sidney Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, PA 19107, USA
b Institute of Pharmacy, Pharmaceutical College, Henan University, Kaifeng, Henan 475004, China
c Department of Medicine, Division of Hematology and Oncology, Robert H Lurie Comprehensive Cancer Center, Feinberg School of Medicine, Northwestern University, Chicago, IL 60611, USA d Department of Pharmacology and Experimental Therapeutics, Thomas Jefferson University, Philadelphia, PA 19107, USA